SY4.2. Seronegative myasthenia gravis: Auto-antibody profiles and clinical features. Issue 8 (August 2021)

• Record Type: Journal Article
• Authors: Hong, Yoon-Ho
• Is Part Of: Clinical neurophysiology. Volume 132:Issue 8(2021)
• Page Start: e44
• Page End: e45
• Publication Date: 2021-08
• Subjects: Neurophysiology -- Periodicals; Electroencephalography -- Periodicals; Electromyography -- Periodicals; Neurology -- Periodicals; 612.8
• DOI: 10.1016/j.clinph.2021.02.041
• Languages: English
• ISSNs: 1388-2457

Abstract

Abstract : Acquired myasthenia gravis (MG) is a prototype autoimmune disease of the neuromuscular junction, caused in most patients by antibodies to the muscle nicotinic acetylcholine receptor (AChR). There seem to be ethnic and regional differences in the frequency and clinical features of MG seronegative for the AChR antibody. However, serological tests based on novel assays and recently identified antigens are not available for routine clinical practice in many regions where the overall frequency and features of seronegative MG according to antibody have not been determined yet. Recently, we performed a multi-centers study in South Korea to investigate the clinical features and autoantibody profiles in adult patients seronegative for AChR antibodies. Serological tests included the antibodies to MuSK (Muscle-specific tyrosine kinase), LRP4 (Lipoprotein receptor- related protein 4), and clustered AChR, In this talk, an overview will be presented that covers the results of our recent study and what is currently known on seronegative MG in Asia from basic epidemiology and clinical features through to treatments.